Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Harvard Business School
Express Scripts
Merck
Colorcon

Last Updated: May 19, 2022

Investigational Drug Information for RG1662


✉ Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug RG1662?

RG1662 is an investigational drug.

There have been 9 clinical trials for RG1662. The most recent clinical trial was a Phase 2 trial, which was initiated on May 5th 2014.

The most common disease conditions in clinical trials are Down Syndrome, Syndrome, and [disabled in preview]. The leading clinical trial sponsors are Hoffmann-La Roche and [disabled in preview].

There are thirteen US patents protecting this investigational drug and one hundred and sixty-one international patents.

Recent Clinical Trials for RG1662
TitleSponsorPhase
A Study of RO5186582 in Down Syndrome Among Children 6 to 11 Years of AgeHoffmann-La RochePhase 2
Basmisanil Positron Emission Tomography Study in Japanese VolunteersHoffmann-La RochePhase 1
A Study to Investigate the Effect of CYP3A Inhibition on the Pharmacokinetics of RG1662 in Healthy SubjectsHoffmann-La RochePhase 1

See all RG1662 clinical trials

Clinical Trial Summary for RG1662

Top disease conditions for RG1662
Top clinical trial sponsors for RG1662

See all RG1662 clinical trials

US Patents for RG1662

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
RG1662 See Plans and Pricing Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) See Plans and Pricing
RG1662 See Plans and Pricing Oral drug dosage forms having desired drug release profiles and uses thereof Triastek, Inc. (Nanjing, CN) See Plans and Pricing
RG1662 See Plans and Pricing Compartmented pharmaceutical dosage forms Triastek, Inc. (Nanjing, CN) See Plans and Pricing
RG1662 See Plans and Pricing Compositions and methods for neurological diseases Coda Biotherapeutics, Inc. (South San Francisco, CA) See Plans and Pricing
RG1662 See Plans and Pricing Isoxazolo-pyridine derivatives Hoffmann-La Roche Inc (Nutley, NJ) See Plans and Pricing
RG1662 See Plans and Pricing Process for the preparation of isoxazolyl-methoxy nicotinic acids Hoffman-La Roche Inc. (Nutley, NJ) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for RG1662

Drugname Country Document Number Estimated Expiration Related US Patent
RG1662 Australia AU2017261372 2036-05-05 See Plans and Pricing
RG1662 Canada CA3023278 2036-05-05 See Plans and Pricing
RG1662 China CN107847398 2036-05-05 See Plans and Pricing
RG1662 European Patent Office EP3452003 2036-05-05 See Plans and Pricing
RG1662 Hong Kong HK1249728 2036-05-05 See Plans and Pricing
RG1662 Japan JP2019520866 2036-05-05 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Harvard Business School
Express Scripts
Merck
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.